Rockwell Medical, Inc. (RMTI)
Chart Events
Performance Outlook
| Previous Close | 2.0400 |
| Open | 1.9800 |
| Bid | 1.9500 x 1400 |
| Ask | 1.9800 x 800 |
| Day's Range | 1.8700 - 2.0100 |
| 52 Week Range | 1.8700 - 11.6600 |
| Volume | |
| Avg. Volume | 46,772 |
| Market Cap | 188.872M |
| Beta (5Y Monthly) | 0.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3460 |
| Earnings Date | Mar 29, 2022 - Apr 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- PR Newswire
Rockwell Medical Provides First Quarter 2022 Financial and Operational Update
Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today reported financial results and a business update for the three months ended March 31, 2022.
- Benzinga
Rockwell Medical Submits Additional Data For IND Application For Iron Deficiency Candidate
Rockwell Medical Inc (NASDAQ: RMTI) has provided the FDA with the supplemental data requested by the agency in December 2021 for its pending Investigational New Drug (IND) application of Ferric Pyrophosphate Citrate (FPC) for iron deficiency. The IND supports the proposed Phase 2 trial of FPC for treating iron deficiency anemia and maintaining hemoglobin in patients receiving infusion therapy in the home setting. The additional data relate to the physical, chemical, and microbiological stability
- PR Newswire
Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial
Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it provided the U.S. Food and Drug Administration (FDA) with the supplemental data, requested by the agency in December 2021, for the Company's pending Investigational New Drug (IND) application in support of a proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC) for the treatment of iron deficiency anemia and m
